ACC 22: Results from the PACIFIC AF Trial | Dr Manesh Patel

Подробнее о видео

Watch on Radcliffe Cardiology:

In this short interview from our coverage of ACC 22 late-breaking trials, Dr Manesh Patel (Duke Heart Center, Durham, NC, USA) discusses the multicentre, randomised, double-blind PACIFIC-AF trial. The trial sought to determine the efficacy of the oral FXIa inhibitor Asundexian and evaluate the safety of the drug, compared to the non-vitamin K oral anticoagulant (NOAC) Apixaban, in treating patients with AF.

Discussion Points:
1. Background to the study
2. Study design
3. Key findings
4. Next steps
5. Take-home messages

Recorded remotely from ACC, Washington DC, 2022.
Interviewer: Mirjam Boros

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.